These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 16293880)

  • 41. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation.
    Steckel NK; Koldehoff M; Ditschkowski M; Beelen DW; Elmaagacli AH
    Transplantation; 2007 Jun; 83(11):1518-20. PubMed ID: 17565328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows.
    Zetterberg E; Vannucchi AM; Migliaccio AR; Vainchenker W; Tulliez M; Dickie R; Hasselbalch H; Rogers R; Palmblad J
    Haematologica; 2007 May; 92(5):597-604. PubMed ID: 17488682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of ALK5 inhibition in myelofibrosis.
    Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
    JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
    Spangrude GJ; Lewandowski D; Martelli F; Marra M; Zingariello M; Sancillo L; Rana RA; Migliaccio AR
    Stem Cells; 2016 Jan; 34(1):67-82. PubMed ID: 26439305
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Myelofibrosis with myeloid metaplasia.
    Barosi G
    Hematol Oncol Clin North Am; 2003 Oct; 17(5):1211-26. PubMed ID: 14560783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
    Odenike O; Tefferi A
    Semin Oncol; 2005 Aug; 32(4):422-31. PubMed ID: 16202688
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD133 marks a stem cell population that drives human primary myelofibrosis.
    Triviai I; Stübig T; Niebuhr B; Hussein K; Tsiftsoglou A; Fehse B; Stocking C; Kröger N
    Haematologica; 2015 Jun; 100(6):768-79. PubMed ID: 25724578
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
    Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis.
    Hasselbalch HC
    Med Hypotheses; 2003 Aug; 61(2):244-7. PubMed ID: 12888313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components.
    Castro-Malaspina H
    Prog Clin Biol Res; 1984; 154():427-54. PubMed ID: 6089232
    [TBL] [Abstract][Full Text] [Related]  

  • 52. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
    Tefferi A; Barosi G; Mesa RA; Cervantes F; Deeg HJ; Reilly JT; Verstovsek S; Dupriez B; Silver RT; Odenike O; Cortes J; Wadleigh M; Solberg LA; Camoriano JK; Gisslinger H; Noel P; Thiele J; Vardiman JW; Hoffman R; Cross NC; Gilliland DG; Kantarjian H;
    Blood; 2006 Sep; 108(5):1497-503. PubMed ID: 16675707
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.
    Erba BG; Gruppi C; Corada M; Pisati F; Rosti V; Bartalucci N; Villeval JL; Vannucchi AM; Barosi G; Balduini A; Dejana E
    Am J Pathol; 2017 Aug; 187(8):1879-1892. PubMed ID: 28728747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia.
    Reilly JT
    Semin Oncol; 2005 Aug; 32(4):359-64. PubMed ID: 16202681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.
    Lasho TL; Pardanani A; McClure RF; Mesa RA; Levine RL; Gilliland DG; Tefferi A
    Br J Haematol; 2006 Dec; 135(5):683-7. PubMed ID: 17107350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia.
    Rumi E; Passamonti F; Boveri E; De Amici M; Astori C; Braschi M; Castagnola C; Magrini U; Cazzola M; Lazzarino M
    Am J Hematol; 2006 Feb; 81(2):124-7. PubMed ID: 16432861
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis.
    Jurisic V; Terzic T; Pavlovic S; Colovic N; Colovic M
    Pathol Res Pract; 2008; 204(2):129-32. PubMed ID: 17976926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis.
    Hasselbalch HC; Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA
    Leuk Res; 2011 Oct; 35(10):1330-4. PubMed ID: 21470677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.